205 related articles for article (PubMed ID: 26169261)
1. Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy--the SpheroNEO study.
Halfter K; Ditsch N; Kolberg HC; Fischer H; Hauzenberger T; von Koch FE; Bauerfeind I; von Minckwitz G; Funke I; Crispin A; Mayer B;
BMC Cancer; 2015 Jul; 15():519. PubMed ID: 26169261
[TBL] [Abstract][Full Text] [Related]
2. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
3. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.
Loibl S; Jackisch C; Lederer B; Untch M; Paepke S; Kümmel S; Schneeweiss A; Huober J; Hilfrich J; Hanusch C; Gerber B; Eidtmann H; Denkert C; Costa SD; Blohmer JU; Nekljudova V; Mehta K; von Minckwitz G
Breast Cancer Res Treat; 2015 Jul; 152(2):377-87. PubMed ID: 26109347
[TBL] [Abstract][Full Text] [Related]
4. A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer.
Schipper RJ; Moossdorff M; Nelemans PJ; Nieuwenhuijzen GA; de Vries B; Strobbe LJ; Roumen RM; van den Berkmortel F; Tjan-Heijnen VC; Beets-Tan RG; Lobbes MB; Smidt ML
Clin Breast Cancer; 2014 Oct; 14(5):315-22. PubMed ID: 24548732
[TBL] [Abstract][Full Text] [Related]
5. Nottingham Clinico-Pathological Response Index (NPRI) after neoadjuvant chemotherapy (Neo-ACT) accurately predicts clinical outcome in locally advanced breast cancer.
Abdel-Fatah TM; Ball G; Lee AH; Pinder S; MacMilan RD; Cornford E; Moseley PM; Silverman R; Price J; Latham B; Palmer D; Chan A; Ellis IO; Chan SY
Clin Cancer Res; 2015 Mar; 21(5):1052-62. PubMed ID: 25520390
[TBL] [Abstract][Full Text] [Related]
6. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer.
Chen S; Liu Y; Ouyang QW; Huang L; Luo RC; Shao ZM
Ann Surg Oncol; 2015 Jan; 22(1):32-9. PubMed ID: 25012266
[TBL] [Abstract][Full Text] [Related]
8. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
9. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
10. Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis.
Luengo-Gil G; González-Billalabeitia E; Chaves-Benito A; García Martínez E; García Garre E; Vicente V; Ayala de la Peña F
Breast Cancer Res Treat; 2015 Jun; 151(3):577-87. PubMed ID: 25967462
[TBL] [Abstract][Full Text] [Related]
11. Clinical usefulness and relevance of intermediate endpoints for cytotoxic neoadjuvant therapy.
Fontanella C; Loibl S; von Minckwitz G
Breast; 2015 Nov; 24 Suppl 2():S84-7. PubMed ID: 26279131
[TBL] [Abstract][Full Text] [Related]
12. Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids.
Halfter K; Hoffmann O; Ditsch N; Ahne M; Arnold F; Paepke S; Grab D; Bauerfeind I; Mayer B
J Transl Med; 2016 May; 14(1):112. PubMed ID: 27142386
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.
Yardley DA; Peacock NW; Shastry M; Burris HA; Bechhold RG; Hendricks CB; Yoshizawa CN; Sing AP; Hainsworth JD
Breast Cancer Res Treat; 2015 Nov; 154(2):299-308. PubMed ID: 26507191
[TBL] [Abstract][Full Text] [Related]
14. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
15. Role of the Apparent Diffusion Coefficient in the Prediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer.
Bufi E; Belli P; Costantini M; Cipriani A; Di Matteo M; Bonatesta A; Franceschini G; Terribile D; Mulé A; Nardone L; Bonomo L
Clin Breast Cancer; 2015 Oct; 15(5):370-80. PubMed ID: 25891905
[TBL] [Abstract][Full Text] [Related]
16. Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.
Sánchez-Muñoz A; Navarro-Perez V; Plata-Fernández Y; Santonja A; Moreno I; Ribelles N; Alba E
Clin Breast Cancer; 2015 Oct; 15(5):343-7. PubMed ID: 25752727
[TBL] [Abstract][Full Text] [Related]
17. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
18. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials.
Fontanella C; Lederer B; Gade S; Vanoppen M; Blohmer JU; Costa SD; Denkert C; Eidtmann H; Gerber B; Hanusch C; Hilfrich J; Huober J; Schneeweiss A; Paepke S; Jackisch C; Mehta K; Nekljudova V; Untch M; Neven P; von Minckwitz G; Loibl S
Breast Cancer Res Treat; 2015 Feb; 150(1):127-39. PubMed ID: 25677740
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.
Marinovich ML; Houssami N; Macaskill P; Sardanelli F; Irwig L; Mamounas EP; von Minckwitz G; Brennan ME; Ciatto S
J Natl Cancer Inst; 2013 Mar; 105(5):321-33. PubMed ID: 23297042
[TBL] [Abstract][Full Text] [Related]
20. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
